1. Health
Jennifer Moll, PharmD

FDA Approves Juxtapid for Familial Hypercholesterolemia

By December 27, 2012

Follow me on:

Aegerion Pharmaceuticals recently announced that its new cholesterol-lowering medication, Juxtapid, was approved by the Food and Drug Administration (FDA). Juxtapid (lomitapide) primarily lowers LDL cholesterol and is indicated for individuals who have been diagnosed with the inherited condition, homozygous familial hypercholesterolemia

Juxtapid is a new class of cholesterol-lowering medication and works by inhibiting microsomal triglyceride transfer protein (MTTP), a protein that helps assemble lipoproteins containing apoB. This prevents VLDL -- and LDL --  from being made in the body, lowering LDL levels.

The new drug should be available sometime in January 2013.

No comments yet. Leave a Comment
Leave a Comment

Line and paragraph breaks are automatic. Some HTML allowed: <a href="" title="">, <b>, <i>, <strike>

©2014 About.com. All rights reserved.

We comply with the HONcode standard
for trustworthy health
information: verify here.